N
VRDN icon

Natixis’s Viridian Therapeutics VRDN Stock Holding History

Natixis’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-19,317
Closed -$421K – 1245
2023
Q4 		$421K Buy
+19,317
New +$305K ﹤0.01% 644

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Natixis's VRDN Position: Q1 2024 in Review

Natixis sold out of Viridian Therapeutics (VRDN) in Q1 2024, closing a stake of 19,317 shares — an estimated $421K sold.

Natixis first reported a position in VRDN in Q4 2023 and held it in 1 quarter. The position peaked at $421K in Q4 2023. 136 funds tracked by Wall St. Rank hold VRDN as of Q1 2024.

  • Natixis reported no remaining Viridian Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Natixis sold 19,317 Viridian Therapeutics shares in Q1 2024, an estimated $421K.
  • Natixis first reported a position in Viridian Therapeutics in Q4 2023 and held it in 1 quarter.
  • Natixis's Viridian Therapeutics position peaked at $421K in Q4 2023.
  • 136 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2024.

Based on Natixis's 13F filing for Q1 2024, filed 13 May 2024.